Cyclic tetrapeptides
Cyclic tetrapeptides that are kappa opioid receptor (KOR) antagonists can be used in therapeutic applications for treating, inhibiting, and/or preventing drug addiction, drug use, or drug seeking behavior in a subject. This can include subjects that have a history of drug addiction. The drug can be selected from cocaine, alcohol, amphetamines, methamphetamines, nicotine, opiate, or combinations thereof. These cyclic tetrapeptides can also be useful for treating, inhibiting, and/or preventing stress-induced drug seeking behavior.
1. A cyclic tetrapeptide, wherein the cyclic tetrapeptide comprises a structure of Scaffold 1 or a derivative thereof:
wherein the
portion of the Dab, Lys, Arg, Orn, (4NH 2 )Phe, (3NH 2 )Phe, Ser, Val, Ile, Leu, and Gly structures is of Scaffold 1.
2. A cyclic tetrapeptide as in claim 1 , wherein the Phe-2 residue is substituted with any Phe analog.
3. A cyclic tetrapeptide as in claim 2 , wherein the Phe analog is one of Tyr, mTyr, Tryp, 1-Nal, 2-Nal, cyclhexylalanine, Leu, aliphatic amino acids, and derivatives thereof.
4. A cyclic tetrapeptide, wherein the cyclic tetrapeptide comprises a structure of Scaffold 2 or a derivative thereof:
wherein the
portion of the Dab, Lys, Arg, Orn, (4NH 2 )Phe, (3NH 2 )Phe, Ser, Tyr, Val, Ile, Leu, and Gly structures is of Scaffold 2.
5. A cyclic tetrapeptide, wherein the cyclic tetrapeptide comprises a structure of Scaffold 3 or a derivative thereof:
wherein the
portion of the Tyr, 1-Nal, 2-Nal, Dab, Lys, Arg, Orn, (4NH 2 )Phe, (3NH 2 )Phe, Ser, Val, Ile, Leu, and Gly structures is of Scaffold 3.
6. A cyclic tetrapeptide, wherein the cyclic tetrapeptide comprises a structure of Scaffold 4 or a derivative thereof:
wherein the
portion of the Tyr, 1-Nal, 2-Nal, Dab, Lys, Arg, Orn, (4NH 2 )Phe, (3NH 2 )Phe, Ser, Val, Ile, Leu, and Gly structures is of Scaffold 4.
7. A cyclic tetrapeptide having KOR antagonist and/or agonist activity, the cyclic tetrapeptide comprising one of cyclo[Trp-Ala-D-Pro-Phe], cyclo[Ala-Phe-D-Pro-Phe], cyclo[Trp-Phe-D-Pro-Ala], cyclo[Trp-Phe-N-Me-D-Ala-Phe], cyclo[Trp-Phe-Aib-Phe], cyclo[D-Trp-Ala-D-Pro-Phe], cyclo[D-Ala-Phe-D-Pro-Phe], cyclo[D-Trp-Phe-D-Pro-Ala], cyclo[D-Trp-Phe-NMeD-Ala-Phe], or a derivative thereof.
8. A cyclic tetrapeptide as in claim 7 , wherein the cyclic tetrapeptide KOR antagonist is one of cyclo[Trp-Ala-D-Pro-Phe], cyclo[D-Trp-Ala-D-Pro-Phe], or derivative thereof.
9. A cyclic tetrapeptide as in claim 8 , wherein the cyclic tetrapeptide KOR antagonist is cyclo[Trp-Ala-D-Pro-Phe], cyclo[D-Trp-Ala-D-Pro-Phe], or derivative thereof.
10. A cyclic tetrapeptide as in claim 7 having at least 3 times more KOR antagonist activity compared to CJ 15,208.
11. A pharmaceutical composition comprising:
a therapeutically effective amount of the cyclic tetrapeptide of claim 7 .
12. A method for agonizing kappa-opioid receptors (KOR) present in tissue in vitro or in vivo, the method comprising:
administering at least one cyclic tetrapeptide KOR agonist to the tissue in an amount sufficient to agonize the KOR in the tissue, wherein the cyclic tetrapeptide KOR agonist is one of cyclo[Trp-Ala-D-Pro-Phe], cyclo[Ala-Phe-D-Pro-Phe], cyclo[Trp-Phe-D-Pro-Ala], cyclo[Trp-Phe-N-Me-D-Ala-Phe], cyclo[Trp-Phe-Aib-Phe], cyclo[D-Trp-Ala-D-Pro-Phe], cyclo[D-Ala-Phe-D-Pro-Phe], cyclo[D-Trp-Phe-D-Pro-Ala], cyclo[D-Trp-Phe-NMeD-Ala-Phe], or a derivative thereof.
13. A method for antagonizing kappa-opioid receptors (KOR) present in tissue in vitro or in vivo, the method comprising:
administering at least one cyclic tetrapeptide KOR antagonist to the tissue in an amount sufficient to antagonize the KOR in the tissue, wherein the cyclic tetrapeptide KOR antagonist is one of cyclo[Trp-Ala-D-Pro-Phe], cyclo[Ala-Phe-D-Pro-Phe], cyclo[Trp-Phe-D-Pro-Ala], cyclo[Trp-Phe-N-Me-D-Ala-Phe], cyclo[Trp-Phe-Aib-Phe], cyclo[D-Trp-Ala-D-Pro-Phe], cyclo[D-Ala-Phe-D-Pro-Phe], cyclo[D-Trp-Phe-D-Pro-Ala], cyclo[D-Trp-Phe-NMeD-Ala-Phe], or a derivative thereof.
14. A method as in claim 1 , wherein the cyclic tetrapeptide KOR antagonist is one of cyclo[Trp-Ala-D-Pro-Phe], cyclo[D-Trp-Ala-D-Pro-Phe], or derivative thereof.
15. A method as in claim 14 , wherein the cyclic tetrapeptide KOR antagonist is cyclo[Trp-Ala-D-Pro-Phe], cyclo[D-Trp-Ala-D-Pro-Phe], or derivative thereof.
16. A method as in claim 13 , wherein the cyclic tetrapeptide KOR antagonist is selective for KOR over MOR or DOR.
17. A method as in claim 13 , wherein the cyclic tetrapeptide KOR antagonist has at least about 3-fold more effectiveness compared to CJ 15,208 having the structure of Formula 1.
18. A method as in claim 13 , wherein the tissue is located within a subject.
19. A method as in claim 18 , wherein the cyclic tetrapeptide KOR antagonist is administered to a human subject having the tissue in an effective amount sufficient to cross the blood brain barrier and antagonize the KOR to provide a therapeutic effect.
20. A method as in claim 19 , further comprising:
administering a therapeutically effective amount of the cyclic tetrapeptide KOR antagonist to a subject having the tissue for treating and/or inhibiting drug addiction, drug use, or drug seeking behavior in the subject.
21. A method as in claim 20 , further comprising identifying the subject to have a history of drug addiction.
22. A method as in claim 20 , wherein the drug is selected from cocaine, alcohol, amphetamines, methamphetamines, nicotine, opiate, or combinations thereof.
23. A method as in claim 20 , wherein the administering is for treating and/or inhibiting drug seeking behavior and the drug seeking behavior is stress induced and/or a relapse.
24. A method as in claim 13 , further comprising:
administering a therapeutically effective amount of the cyclic tetrapeptide KOR antagonist to a subject having the tissue for treating and/or inhibiting depression or anxiety.